An Analgesic Future for Anavex Life Sciences Corp?
Now, with the patent-protected potential of AV1066 being able to treat nociceptive and neuropathic pain, as with the other Anavex molecules entering human trials for other diseases and conditions, when they happen, we will watch closely the results of clinical trials of this new drug.
If the drug proves safe and effective in humans, would there be much of a market for it? How many suffer from "nociceptive and neuropathic pain?" Might AV1066 be free of the many obviating side effects of conventional pain drugs? How will it compare, say, to morphine?
So that all of the usuals won't have to, I'll diligently suggest that no one should buy a single AVXL share in speculative anticipation of Anavex revenues from this new analgesic. It may not prove effective or safe; may never be approved for sale or therapy. We'll have to wait and see.
But, if it proves to work in humans? Well, run your own numbers. A lota people have nociceptive and neuropathic pains.